Plonmarlimab Biosimilar – Anti-CSF2 mAb – Research Grade

Introduction

Plonmarlimab Biosimilar, also known as Anti-CSF2 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Dupilumab. It targets the cytokine colony-stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody has been extensively studied and has shown promising results in preclinical and clinical trials, making it a potential therapeutic option for various inflammatory and autoimmune diseases.

Structure of Plonmarlimab Biosimilar

Plonmarlimab Biosimilar is a humanized monoclonal antibody, meaning it is derived from non-human sources but has been modified to be more similar to human antibodies. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the target CSF2 molecule, while the Fc region is involved in immune effector functions.

Mechanism of Action

CSF2 is a cytokine that plays a crucial role in the differentiation and activation of immune cells, including macrophages, neutrophils, and dendritic cells. These cells are involved in the inflammatory response and are implicated in various autoimmune and inflammatory diseases. By targeting CSF2, Plonmarlimab Biosimilar inhibits its activity and prevents the recruitment and activation of these immune cells, leading to a decrease in inflammation.

Therapeutic Applications

Plonmarlimab Biosimilar has shown potential in the treatment of various inflammatory and autoimmune diseases. It has been studied in preclinical and clinical trials for the treatment of conditions such as rheumatoid arthritis, psoriasis, atopic dermatitis, and asthma. In a phase II clinical trial, Plonmarlimab Biosimilar showed significant improvement in patients with moderate to severe atopic dermatitis, with a reduction in disease severity and symptoms. It has also shown promising results in patients with moderate to severe asthma, with a decrease in the frequency and severity of asthma attacks.

Advantages of Plonmarlimab Biosimilar

As a biosimilar to Dupilumab, Plonmarlimab Biosimilar has several advantages over other therapeutic options. It has a high affinity for CSF2, making it highly effective in inhibiting its activity. It also has a longer half-life compared to Dupilumab, allowing for less frequent dosing and potentially improving patient compliance. Additionally, as a biosimilar, Plonmarlimab Biosimilar has been shown to have similar efficacy and safety profiles to Dupilumab, making it a more affordable option for patients.

Conclusion

In summary, Plonmarlimab Biosimilar, also known as Anti-CSF2 mAb, is a promising therapeutic option for various inflammatory and autoimmune diseases. Its high affinity for CSF2 and longer half-life make it an effective and convenient treatment option for patients. With further research and clinical trials, Plonmarlimab Biosimilar has the potential to improve the lives of patients suffering from these debilitating conditions.

ProteoGenix catalogue number PX-TA1705. For research use only.

Target: Plonmarlimab Biosimilar – Anti-CSF2 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet